ADMA Biologics, Inc. (ADMA): Shareholders' Equity
$477.32M
As of 2025-12-31
$408.21M
As of 2026-06-30
+46.4%
3-year compound annual growth
+40.2%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $477.32M | +36.8% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $349.02M | +158.1% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $135.21M | -11.0% | 2026-02-25, Balance as of period end |
| 2022-12-31 | $151.97M | +7.7% | 2025-03-18, Balance as of period end |
| 2021-12-31 | $141.17M | +60.0% | 2024-02-28, Balance as of period end |
| 2020-12-31 | $88.25M | +236.9% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $26.19M | +32.5% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $19.77M | -51.0% | 2020-03-13, Balance as of period end |
| 2017-12-31 | $40.33M | n/m | 2019-03-13, Balance as of period end |
| 2016-12-31 | -$4.46M | n/m | 2018-03-29, Balance as of period end |
| 2015-12-31 | $821.0K | -86.3% | 2017-02-24, Balance as of period end |
| 2014-12-31 | $6.01M | -72.1% | 2016-03-23, Balance as of period end |
| 2013-12-31 | $21.57M | +128.9% | 2015-03-09, Balance as of period end |
| 2012-12-31 | $9.42M | n/m | 2014-03-28, Balance as of period end |
| 2011-12-31 | $385.8K | n/a | 2013-03-06, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $477.32M | +36.8% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $343.43M | +53.0% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $381.03M | +5.6% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $1.22B | +28.9% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $472.96M | +0.1% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.11B | +6.8% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | -$119.15M | n/m |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $218.79M | +7.9% |
| Vericel Corp (VCEL) | 2025-12-31 | $354.64M | +21.5% |
Compare ADMA, TARS, IMCR, KRYS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗